363 related articles for article (PubMed ID: 31387281)
1. Liquid Biopsy as a Tool for Differentiation of Leiomyomas and Sarcomas of Corpus Uteri.
Dvorská D; Škovierová H; Braný D; Halašová E; Danková Z
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387281
[TBL] [Abstract][Full Text] [Related]
2. Different methylation levels in the KLF4, ATF3 and DLEC1 genes in the myometrium and in corpus uteri mesenchymal tumours as assessed by MS-HRM.
Braný D; Dvorská D; Grendár M; Ňachajová M; Szépe P; Lasabová Z; Žúbor P; Višňovský J; Halášová E
Pathol Res Pract; 2019 Aug; 215(8):152465. PubMed ID: 31176573
[TBL] [Abstract][Full Text] [Related]
3. Telomerase activity in needle biopsied uterine myoma-like tumors: differential diagnosis between uterine sarcomas and leiomyomas.
Tsujimura A; Kawamura N; Ichimura T; Honda K; Ishiko O; Ogita S
Int J Oncol; 2002 Feb; 20(2):361-5. PubMed ID: 11788902
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel diagnostic gene expression signature to discriminate uterine leiomyoma from leiomyosarcoma.
Adams CL; Dimitrova I; Post MD; Gibson L; Spillman MA; Behbakht K; Bradford AP
Exp Mol Pathol; 2019 Oct; 110():104284. PubMed ID: 31301306
[TBL] [Abstract][Full Text] [Related]
5. Molecular differential diagnosis of uterine leiomyomas and leiomyosarcomas.
Mas A; Simón C
Biol Reprod; 2019 Dec; 101(6):1115-1123. PubMed ID: 30184111
[TBL] [Abstract][Full Text] [Related]
6. Molecular prognostication of uterine smooth muscle neoplasms: From CGH array to CINSARC signature and beyond.
Croce S; Chibon F
Genes Chromosomes Cancer; 2021 Mar; 60(3):129-137. PubMed ID: 33099852
[TBL] [Abstract][Full Text] [Related]
7. Liquid Biopsy: A New Translational Diagnostic and Monitoring Tool for Musculoskeletal Tumors.
Hadjimichael AC; Pergaris A; Kaspiris A; Foukas AF; Theocharis SE
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768955
[TBL] [Abstract][Full Text] [Related]
8. Identification of uterine leiomyoma-specific marker genes based on DNA methylation and their clinical application.
Sato S; Maekawa R; Yamagata Y; Tamura I; Lee L; Okada M; Jozaki K; Asada H; Tamura H; Sugino N
Sci Rep; 2016 Aug; 6():30652. PubMed ID: 27498619
[TBL] [Abstract][Full Text] [Related]
9. The differential diagnoses of uterine leiomyomas and leiomyosarcomas using DNA and RNA sequencing.
Mas A; Alonso R; Garrido-Gómez T; Escorcia P; Montero B; Jiménez-Almazán J; Martín J; Pellicer N; Monleón J; Simón C
Am J Obstet Gynecol; 2019 Oct; 221(4):320.e1-320.e23. PubMed ID: 31121144
[TBL] [Abstract][Full Text] [Related]
10. Benign metastasizing leiomyoma of the lung: clinicopathologic, immunohistochemical, and micro-RNA analyses.
Nuovo GJ; Schmittgen TD
Diagn Mol Pathol; 2008 Sep; 17(3):145-50. PubMed ID: 18382364
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the predictivity of preoperative serum CA 125 in the differential diagnosis of uterine leiomyoma and uterine sarcoma in the Turkish female population.
Yilmaz N; Sahin I; Kilic S; Ozgu E; Gungor T; Bilge U
Eur J Gynaecol Oncol; 2009; 30(4):412-4. PubMed ID: 19761133
[TBL] [Abstract][Full Text] [Related]
12. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.
Mäkinen N; Kämpjärvi K; Frizzell N; Bützow R; Vahteristo P
Mol Cancer; 2017 Jun; 16(1):101. PubMed ID: 28592321
[TBL] [Abstract][Full Text] [Related]
13. Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridization.
Packenham JP; du Manoir S; Schrock E; Risinger JI; Dixon D; Denz DN; Evans JA; Berchuck A; Barrett JC; Devereux TR; Ried T
Mol Carcinog; 1997 Aug; 19(4):273-9. PubMed ID: 9290705
[TBL] [Abstract][Full Text] [Related]
14. Application of liquid biopsy in bone and soft tissue sarcomas: Present and future.
Li X; Seebacher NA; Hornicek FJ; Xiao T; Duan Z
Cancer Lett; 2018 Dec; 439():66-77. PubMed ID: 30223067
[TBL] [Abstract][Full Text] [Related]
15. Growth differentiation factor-15 as biomarker in uterine sarcomas.
Trovik J; Salvesen HB; Cuppens T; Amant F; Staff AC
Int J Gynecol Cancer; 2014 Feb; 24(2):252-9. PubMed ID: 24401984
[TBL] [Abstract][Full Text] [Related]
16. Exploring chromosomal abnormalities and genetic changes in uterine smooth muscle tumors.
Liegl-Atzwanger B; Heitzer E; Flicker K; Müller S; Ulz P; Saglam O; Tavassoli F; Devouassoux-Shisheboran M; Geigl J; Moinfar F
Mod Pathol; 2016 Oct; 29(10):1262-77. PubMed ID: 27363490
[TBL] [Abstract][Full Text] [Related]
17. h-Caldesmon expression effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors.
Nucci MR; O'Connell JT; Huettner PC; Cviko A; Sun D; Quade BJ
Am J Surg Pathol; 2001 Apr; 25(4):455-63. PubMed ID: 11257619
[TBL] [Abstract][Full Text] [Related]
18. Machine Learning to Differentiate T2-Weighted Hyperintense Uterine Leiomyomas from Uterine Sarcomas by Utilizing Multiparametric Magnetic Resonance Quantitative Imaging Features.
Nakagawa M; Nakaura T; Namimoto T; Iyama Y; Kidoh M; Hirata K; Nagayama Y; Yuki H; Oda S; Utsunomiya D; Yamashita Y
Acad Radiol; 2019 Oct; 26(10):1390-1399. PubMed ID: 30661978
[TBL] [Abstract][Full Text] [Related]
19. Potential Markers to Differentiate Uterine Leiomyosarcomas from Leiomyomas.
Guo J; Zheng J; Tong J
Int J Med Sci; 2024; 21(7):1227-1240. PubMed ID: 38818470
[TBL] [Abstract][Full Text] [Related]
20. Circulating Transcripts and Biomarkers in Uterine Tumors: Is There a Predictive Role?
De Bruyn C; Baert T; Van den Bosch T; Coosemans A
Curr Oncol Rep; 2020 Jan; 22(2):12. PubMed ID: 31997106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
